Contextualizing the Development of Anti-HER2 Therapies for Patients with Advanced Urothelial Carcinoma.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 41654396.
- Also identified by DOI 10.1016/j.eururo.2026.01.027.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Antibody-drug conjugates (ADCs) have revolutionized the treatment landscape for metastatic urothelial carcinoma. Encouraging clinical activity of HER2-directed ADCs, including disitamab vedotin, has been observed in early-phase trials. Recent promising results from the RC48-C016 trial raise important questions. We discuss issues that include optimal frontline treatment selection, subsequent-line treatment sequencing, and the generalizability of the findings.